Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Sabrina BorchertMichael WessollyJan SchmellerElena MairingerJens KollmeierThomas HagerThomas MairingerThomas HeroldDaniel C ChristophRobert F H WalterWilfried E E EberhardtTill PlönesJeremias WohlschlaegerClemens AignerKurt Werner SchmidFabian D MairingerPublished in: BMC cancer (2019)
Defects in HR compiled under the term BRCAness are a common event in MPM. The present data can lead to a better understanding of the underlaying cellular mechanisms and leave the door wide open for new therapeutic approaches for this severe disease with infaust prognosis. Response to Poly (ADP-ribose)-Polymerase (PARP)-Inhibition could be demonstrated in the BAP1-mutated NCI-H2452 cells, especially when combined with cisplatin. Thus, this combination therapy might be effective for up to 2/3 of patients, promising to enhance patients' clinical management and outcome.
Keyphrases
- end stage renal disease
- gene expression
- combination therapy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- dna repair
- prognostic factors
- induced apoptosis
- dna methylation
- peritoneal dialysis
- preterm infants
- machine learning
- early onset
- cell proliferation
- deep learning
- endoplasmic reticulum stress
- cell death
- artificial intelligence
- patient reported
- wild type
- structural basis
- genome wide analysis